-Patients residing in the following clinical states wit! be considered: A. Rising PSA: Patients with a history of localized disease who have undergone definitive radiation or surgery. These patients must demonstrate progression of disease biochemically as outlined below. Patients in this group may not have radiographically evident disease. 
B. Non-castrate metastatic: Patients must present with radiographic evidence of metastatic disease at the time of diagnosis or after treatment for localized disease. These patients must show newly detected disease or progressing disease in bone or in soft tissue. Biochemical progression is defined as: minimum no. of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50% 
Diagnosis of prostate adenocarcinoma histologically confirmed at MSKCC. 
Patient must have level of serum testosterone above the lower limit of normal. 
Karnofskcy performance status (KPS) >_70%. 
Patients must have adequate organ function as defined by the following laboratory criteria: 
WBC >_3500/mm3, platelet count >_100,000/mm3. 
Bilirubin <2.0 mg/dl or SGOT <3.0 X the upper limit of normal. 
Creatinine <_1.6 mg/dl or creatinine clearance >_60 cc/min. 
Prior hormonal therapy is allowed as: 
1. Neoadjuvant treatment prior to radiation therapy or radical prostatectomy, provided that the total duration of exposure does not exceed 10 months. 
2. One cycle of intermittent therapy up to a maximum exposure of 10 months. 
Patients must be at least 18 years of age. 
Patients must have signed an informed consent document stating that they understand the investigational nature of the proposed treatment 

NCT00586898_inc_T3
Measurement
PSA
NCT00586898_inc_T4
Value
Rising
NCT00586898_inc_T5
Observation
history of
NCT00586898_inc_T6
Condition
localized disease
NCT00586898_inc_T7
Procedure
radiation
NCT00586898_inc_T8
Procedure
surgery
NCT00586898_inc_T9
Qualifier
definitive
NCT00586898_inc_T10
Scope
radiation or surgery
NCT00586898_inc_T11
Observation
progression of disease
NCT00586898_inc_T12
Qualifier
biochemically
NCT00586898_inc_T13
Qualifier
radiographically evident
NCT00586898_inc_T14
Condition
disease
NCT00586898_inc_T15
Qualifier
Non-castrate
NCT00586898_inc_T16
Qualifier
metastatic
NCT00586898_inc_T17
Observation
radiographic evidence
NCT00586898_inc_T18
Procedure
radiographic
NCT00586898_inc_T19
Condition
metastatic disease
NCT00586898_inc_T20
Temporal
at the time of diagnosis
NCT00586898_inc_T21
Temporal
after treatment for localized disease
NCT00586898_inc_T22
Procedure
treatment
NCT00586898_inc_T23
Condition
localized disease
NCT00586898_inc_T24
Reference_point
treatment for localized disease
NCT00586898_inc_T25
Reference_point
the time of diagnosis
NCT00586898_inc_T26
Scope
at the time of diagnosis or after treatment for localized disease
NCT00586898_inc_T27
Scope
Non-castrate metastatic
NCT00586898_inc_T28
Temporal
newly detected
NCT00586898_inc_T29
Condition
disease in bone
NCT00586898_inc_T30
Condition
progressing disease in soft tissue
NCT00586898_inc_T31
Condition
disease in soft tissue
NCT00586898_inc_T32
Condition
progressing disease in bone
NCT00586898_inc_T33
Observation
Biochemical progression
NCT00586898_inc_T34
Measurement
Minimal % increase in range of values
NCT00586898_inc_T35
Value
50%
NCT00586898_inc_T36
Measurement
Minimal Baseline PSA value
NCT00586898_inc_T37
Value
(ng/ml): 2
NCT00586898_inc_T38
Measurement
minimum no. of determinations
NCT00586898_inc_T39
Value
3
NCT00586898_inc_T40
Measurement
Interval
NCT00586898_inc_T41
Value
>2 weeks
NCT00586898_inc_T42
Scope
minimum no. of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50%
NCT00586898_inc_T43
Scope
disease or progressing disease in bone or in soft tissue
NCT00586898_inc_T44
Condition
prostate adenocarcinoma
NCT00586898_inc_T45
Procedure
histologically
NCT00586898_inc_T46
Value
confirmed
NCT00586898_inc_T47
Qualifier
histologically confirmed
NCT00586898_inc_T48
Measurement
level of serum testosterone
NCT00586898_inc_T49
Value
above the lower limit of normal
NCT00586898_inc_T50
Measurement
Karnofskcy performance status (KPS)
NCT00586898_inc_T51
Value
>_70%
NCT00586898_inc_T52
Value
adequate
NCT00586898_inc_T53
Measurement
organ function
NCT00586898_inc_T54
Observation
adequate organ function
NCT00586898_inc_T55
Measurement
WBC
NCT00586898_inc_T56
Value
>_3500/mm3
NCT00586898_inc_T57
Measurement
platelet count
NCT00586898_inc_T58
Value
>_100,000/mm3
NCT00586898_inc_T59
Measurement
Bilirubin
NCT00586898_inc_T60
Value
<2.0 mg/dl
NCT00586898_inc_T61
Measurement
SGOT
NCT00586898_inc_T62
Value
<3.0 X the upper limit of normal
NCT00586898_inc_T63
Measurement
Creatinine
NCT00586898_inc_T64
Value
<_1.6 mg/dl
NCT00586898_inc_T65
Measurement
creatinine clearance
NCT00586898_inc_T66
Value
>_60 cc/min
NCT00586898_inc_T67
Temporal
Prior
NCT00586898_inc_T68
Procedure
hormonal therapy
NCT00586898_inc_T69
Mood
is allowed
NCT00586898_inc_T70
Procedure
Neoadjuvant treatment
NCT00586898_inc_T71
Temporal
prior to radiation therapy or radical prostatectomy
NCT00586898_inc_T72
Procedure
radiation therapy
NCT00586898_inc_T73
Procedure
radical prostatectomy
NCT00586898_inc_T74
Reference_point
radiation therapy or radical prostatectomy
NCT00586898_inc_T75
Measurement
total duration of exposure
NCT00586898_inc_T76
Value
does not exceed 10 months
NCT00586898_inc_T77
Multiplier
One cycle
NCT00586898_inc_T78
Procedure
intermittent therapy
NCT00586898_inc_T79
Measurement
maximum exposure
NCT00586898_inc_T80
Value
10 months
NCT00586898_inc_T81
Value
at least 18 years
NCT00586898_inc_T82
Person
age